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Percutaneous maxacalcitol injection therapy regresses
hyperplasia of parathyroid and induces apoptosis in uremia
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Percutaneous maxacalcitol injection therapy regresses hyper-
plasia of parathyroid and induces apoptosis in uremia.
Background. A high level of parathyroid hormone (PTH)
is considered to be an indicator of poor prognosis and a poor
quality of life of dialysis patients; therefore, an effective and
safe therapy for secondary hyperparathyroidism (SHPT) has
been developed.
Methods. In 20 patients with SHPT resistant to maxacalcitol
(OCT) intravenously administered, all detectably enlarged
parathyroid glands were treated by percutaneous maxacalcitol
injection therapy (PMIT) under ultrasonographic guidance
consecutively 6 times, which was followed by OCT that was
intravenously administered. The clinical effects of PMIT were
evaluated based on the changes in the serum intact-PTH, ad-
justed Ca, phosphorus, and bone marker levels, and the para-
thyroid gland volume determined by ultrasonography. Mor-
phologic examination, apoptosis analysis, and PTH mRNA
expression level determination by reverse transcription-poly-
merase chain reaction (RT-PCR) using parathyroid tissues ob-
tained by a biopsy technique were performed.
Results. PMIT and subsequent intravenous OCT adminis-
trations significantly decreased the serum intact-PTH level and
parathyroid gland volume for at least 12 weeks after PMIT
without major complications. Parathyroid tissues obtained
after PMIT exhibited some partial defects of parathyroid cells,
a marked increase in the number of the terminal deoxynucleoti-
dyl transferase-mediated dUTP nick end-labeling (TUNEL)–
positive cells, the ladder formation determined by DNA elec-
trophoresis, and the decrease in the PTH mRNA expression
level.
Conclusion. PMIT is effective and safe for the treatment of
refractory SHPT, and a locally high level of OCT suppresses
PTH secretion and regresses parathyroid hyperplasia, which is
involved in the induction of apoptosis of parathyroid cells.
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Secondary hyperparathyroidism (SHPT) caused by
chronic renal failure results in complications such as re-
nal osteodystrophy. In addition, high levels of parathyroid
hormone (PTH) induce anemia resistant to recombinant
human erythropoietin treatment, cardiovascular disor-
ders, and ectopic calcification, among others [1, 2].
Recently, new active vitamin D derivatives for control-
ling SHPT have been developed. However, for severe
SHPT resistant to these agents, direct injection of a high
concentration of vitamin D into the parathyroid gland
was attempted to suppress parathyroid function [3]. The
development of ultrasonography has enabled the perfor-
mance of percutaneous ethanol injection therapy (PEIT)
in patients with refractory SHPT, and PEIT is known to
be as effective as parathyroidectomy-autotransplanta-
tion (PTx-AT) [4]. However, there are some problems
with PEIT.
Maxacalcitol (22-oxacalcitriol; OCT) is an analog of
1,25-dihydroxy vitamin D3 (1,25-D3) and has been shown
to strongly suppress parathyroid function dose depen-
dently and to improve bone disorder caused by SHPT
in chronic dialysis patients [5, 6]. Experimentally, it has
been proved that OCT suppresses PTH mRNA expres-
sion in uremic rats without causing hypercalcemia and
prevents the decrease in the vitamin D receptor (VDR)
expression level in parathyroid gland as well as that of
1,25-D3 [7–9]. Thus, we developed a direct percutaneous
injection therapy of maxacalcitol (PMIT) into parathy-
roid glands. We applied this for the treatment of refrac-
tory SHPT and examined the in vivo effects on parathy-
roid cells.
METHODS
Patients
Twenty patients with end-stage renal disease (ESRD)
and undergoing regular hemodialysis [mean duration of
hemodialysis therapy, 13.5  4.24 (from 4 to 20) years]
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Table 1. Background features of patients
Demographic data
Number of patients 20 (10 male, 10 female)
Underlying renal disease CGN, 17
Nephrosclerosis, 2
Unknown, 1
Age yrs 55.49.76 (from 39 to 72)
Duration of dialysis yrs 13.54.24 (from 4 to 20)
Baseline data
Serum intact-PTH level pg/mL 1018450
Serum adjusted Ca level mg/dL 11.30.65
Serum phosphorus level mg/dL 6.731.49
Serum BAP level IU/L 233155
Serum intact-BGP level ng/mL 278182
Number of enlarged
parathyroid glands 3.551.32
Total volume of parathyroid
glands cm3 1.981.21
Z-score by DEXA 2.111.65
Abbreviations are: CGN, chronic glomerulonephritis; BAP, bone alkaline phos-
phatase; BGP, bone Gla-protein; DEXA, dual energy x-ray absorptiometry. Data
are mean  SD.
participated in our study (Table 1). All of them had a
complication of severe SHPT that was resistant to OCT
intravenously administered for more than 3 months. The
patients underwent dialysis for 240 minutes 3 times a
week, and bicarbonate dialysate was used in all cases.
The dialysate calcium (Ca) concentration was 1.5 mmol/L
for most of the patients; however, 1.25 mmol/L Ca was
used for 4 patients with hypercalcemia after PMIT. The
types of dialysis membrane used were cellulose acetate
for 8 patients, polysulfone for 10 patients, and polymethyl-
methacrylate for 2 patients. The mean Kt/V was 1.52 
0.31. Blood flow was between 150 to 220 mL/min, and
dialysate flow was 500 mL/min. This study was approved
by the local medical ethics committee, and informed
consent was obtained from each patient.
Percutaneous maxacalcitol injection therapy (PMIT)
and biopsy of parathyroid glands
Enlarged parathyroid glands were examined by ultra-
sonography (SSD 5500; Aloka, Tokyo, Japan) and their
sizes were estimated by three-dimensional measurement
(/6  a  b  c) [10]. PMIT was performed using the
same type of needle developed for PEIT (KM-N type;
Hakko, Tokyo, Japan) [4]. Under ultrasonographic guid-
ance, the needle was inserted into the center of parathy-
roid glands without any anesthesia. If the parathyroid
gland was large, we injected various sites in order to
saturate the entire parathyroid gland with OCT solution.
PMIT was performed consecutively six times a week.
The injected volume of OCT solution (10 or 5 g/mL)
was almost the same for each gland (mean dose of OCT,
15.8  5.25 g/injection for total glands). The dose and
the total volume of parathyroid glands showed a good
correlation (R2  0.871, P  0.01). Table 2 shows the
parathyroid gland volume of each patient and the injected
dose and volume of OCT per one PMIT. In patients with
multiple enlarged parathyroid glands, all detectably en-
larged glands were treated by PMIT simultaneously,
even if they existed bilaterally.
In 13 patients (Table 2), parathyroid gland tissues were
obtained by biopsy under ultrasonographic guidance, us-
ing the same technique as in PMIT, with an 18-guage
needle (Bard MonoptyTM; C.R. Bard, Covington, GA,
USA) before and after (i.e., immediately before the sixth
PMIT) PMIT under local anesthesia with 1% lidocaine.
Therefore, only the sixth PMIT was performed under
local anesthesia in these patients for the complete second
biopsy.
After a series of PMIT, all patients were intravenously
administered with OCT at the end of each hemodialysis
session. The initial dose was 10 g for each hemodialysis
and was changed according to the serum Ca and intact-
PTH (iPTH) levels measured periodically.
Laboratory measurements and radiologic examinations
The serum iPTH, adjusted Ca [adjusted Ca (mg/dL),
Ca (mg/dL)  4  albumin (g/dL)] [11], inorganic phos-
phorus (P) levels, and other biochemical data were ob-
tained before and immediately after (i.e., prior to the
first hemodialysis session after a series of PMIT) PMIT
in all the patients. Moreover, for 18 patients, these data
were also obtained 4 and 12 weeks after PMIT. In order
to detect complications of PMIT in the early phase, the
levels of Ca and P were measured before each hemodial-
ysis session during the week of PMIT. We also measured
serum bone alkaline phosphatase (BAP) and intact bone
Gla-protein (iBGP) levels in 18 patients before and 12
weeks after PMIT in order to examine changes in bone
metabolism caused by PMIT. Moreover, these labora-
tory data of 24 weeks after PMIT were obtained from
14 patients that did not require other treatments for
insufficient PTH suppression.
Serum iPTH levels were measured with the two-anti-
body method using AllegroTM intact-PTH (Nichols Insti-
tute Diagnostics, San Juan Capistrano, CA, USA). Se-
rum BAP levels were measured by precipitation with
wheat-germ lectin using an Iso-ALP test kit (Roche Di-
agnostics GmbH, Mannheim, Germany) and iBGP levels
by immunoradiometric assay using a BGP-immunoradi-
ometric assay (IRMA) kit (Yuka-Medias, Tokyo, Japan)
(upper limit, 150 IU/L; 12.7 ng/mL, respectively). The
levels of serum Ca, P, and albumin were determined with
an automated analyzer (TBA-200FR; Toshiba, Tokyo,
Japan). The individual parathyroid gland volumes were
also determined before and 12 weeks after PMIT in 18
patients using ultrasonography.
The bone mineral density was measured at the radius
one-third the distal portion of the nonarteriovenous fis-
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Table 3. Primer design and size of fragment
Sense primer Antisense primer Size bp
PTH 5	-ATGATACCTGCAAAAGACAT-3	 5	-TTTAGCTTTAGTTAATACA-3	 339
GAPDH 5	-CGCCTGGTCACCAGGGCTGC-3	 5	-CTTACTCCTTGGAGGCCATGT-3	 963
Abbreviations are: PTH, parathyroid hormone; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; bp, base pairs.
tula side by dual energy x-ray absorptiometry (DEXA)
(DPX-L; GE Lunar, Madison, WI, USA). Technetium-
99m methoxyisobutylisonitrile imaging (99mTc-MIBI) or
thallium-201-technetium-99m subtraction scintigraphy
(Tl-Tc) of parathyroid glands was performed for all the
patients in order to rule out the existence of ectopic para-
thyroid gland.
Morphologic examination and apoptosis detection
Parathyroid gland specimens obtained by needle biopsy
(before and after PMIT) were fixed with 4% paraformal-
dehyde phosphate-buffered saline (PBS) for 8 hours and
embedded in paraffin for routine tissue processing. Sec-
tions of these specimens were prepared and stained with
hematoxylin and eosin. We identified all specimens with
parathyroid tissues and then carried out the following
studies. The morphologic changes following PMIT were
examined under a light microscope (BX50; Olympus,
Tokyo, Japan).
For the examination of apoptosis induced by PMIT,
we used the terminal deoxynucleotidyl transferase-medi-
ated dUTP nick end-labeling (TUNEL) method for spec-
imens obtained from 13 patients before and after PMIT.
Paraffin-embedded tissue blocks were sectioned, depara-
ffinized in xylene and alcohol, and placed in PBS. The
tissue sections were then treated with proteinase K and
washed. An in situ apoptosis detection kit, TACS XL
(R & D Systems, Minneapolis, MN, USA) was used
for labeling the free 3	-OH terminus. The number of
TUNEL-positive cells was determined in randomly cho-
sen fields for all tissues under a light microscope. Three
independent observers counted the TUNEL-positive
cells in 10 high-power fields with approximately 200 cells
per field at 400 magnification and then the average
was taken.
Furthermore, we also performed DNA electrophoresis
to detect DNA fragmentation, which is a characteristic
feature of cell apoptosis [12]. From the biopsied parathy-
roid gland specimens (before and after PMIT, in 7 patients,
shown in Table 2), DNA was extracted using a DNA
extraction kit QIAampTM (QIAgen GmbH, Hilden, Ger-
many). DNA electrophoresis was performed at a con-
stant voltage of 100 V in horizontal 2% agarose gels.
DNA bands were visualized by ethidium bromide staining.
Isolation of total RNA and reverse transcription-
polymerase chain reaction (RT-PCR) for PTH
Total RNA was prepared from biopsied parathyroid
gland specimens (before and after PMIT for 8 patients,
shown in Table 2) using the TRIzol reagent (Life Tech-
nologies, Rockville, MD, USA). Total RNA (2 g) was
digested with DNase I (RNase-free) for 10 minutes at
37
C in the presence of 5 U of RNase inhibitor. After
heat inactivation of DNase I, total RNA was reverse
transcribed for 50 minutes at 42
C using SuperScript II
Reverse Transcriptase and oligo (dT) as a primer (Life
Technologies). The reaction was terminated by heating
samples at 70
C.
Subsequently, 1 L of the cDNA mixture was sus-
pended in a total volume of 50 L of a solution con-
taining 50 mmol/L KCl, 10 mmol/L Tris-HCl, 1.2 mmol/L
MgCl2, 0.5 mol/L of each primer, 200 mol/L of each
nucleotide and 1 U of Ampli-Taq GoldTM DNA Polymer-
ase (Roche Molecular Systems, Branchburg, NJ , USA).
Amplification was then performed using specific primers
(Table 3). For each specific assay, PCR conditions were
optimized with respect to the template cDNA per tube,
annealing temperature, and number of cycles. For nor-
malization in this assay, the sample RNA was also ampli-
fied using primers for the housekeeping gene encoding
glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
Amplification products were analyzed on 2% agarose
gels containing 0.5 g/mL ethidium bromide and then
photographed. PCR products of PTH and GAPDH were
quantitated using NIH Image (National Institutes of
Health, Bethesda, MD, USA). For each sample, PTH
mRNA levels were then normalized by GAPDH mRNA
levels. To compile the results of densitometric analysis
from independent experiments, PTH/GAPDH mRNA
ratios for individual patients (N  8) were averaged.
Statistical analysis
Data were expressed as mean  SD. The correlation
between the total parathyroid gland volume measured
by ultrasonography before PMIT and the injected OCT
dose for each PMIT was analyzed. Post-hoc multiple
comparisons using Dunnett tests were performed to de-
termine the significance of differences in values immedi-
ately, 4 weeks, and 12 weeks after PMIT as compared
with those before PMIT. Mann-Whitney U test was used
to determine the significance of differences in the num-
ber of TUNEL-positive cells and the PTH/GAPDH
mRNA ratio. Other laboratory data and changes in the
parathyroid gland volume were analyzed by Student t
test. A P value of less than 0.05 was considered to indi-
cate statistical significance.
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Fig. 1. Changes in serum intact-PTH, adjusted calcium (Ca), and phos-
phorus (P) levels before and after percutaneous maxacalcitol injection
therapy (PMIT) (N 20). After PMIT, serum intact-PTH levels signifi-
cantly decreased, but adjusted serum Ca and P levels did not change
significantly. *P  0.01 vs. before PMIT.
RESULTS
Patient characteristics
Table 1 shows background features of our patients
before PMIT. The mean serum iPTH level was 1018 450
pg/mL, indicating severe hyperparathyroidism in spite
of intravenous OCT administration. The mean serum
adjusted Ca and P levels were 11.3  0.65 and 6.73 
1.49 mg/dL, respectively. Thus, these patients were diag-
nosed as having refractory SHPT resistant to OCT intra-
venously administered. In addition, the high levels of
bone markers (the mean serum BAP and iBGP levels;
233  155 IU/L and 278  182 ng/mL, respectively) and
the low bone mineral content determined by DEXA
(mean Z-score, –2.11  1.65) suggest bone mineral loss
due to high bone–turnover disease resulting from SHPT.
The mean total volume was 1.98  1.21 cm3, and the
mean number of detectably enlarged parathyroid glands
was 3.55  1.32. 99mTC-MIBI or Tl-Tc did not detect any
ectopic parathyroid glands in all 20 patients.
Changes in laboratory data after PMIT
Serum iPTH levels significantly decreased after PMIT
(385  321 pg/mL; P  0.01), and the mean reduction
rate was 62.7  20.3%. In contrast, adjusted serum Ca
and P levels did not change significantly throughout the
course of PMIT (adjusted serum Ca and P levels immedi-
ately after PMIT; 11.6  1.29 and 6.22  1.05 mg/dL,
respectively) (Fig. 1).
We determined the above-mentioned parameters re-
peatedly in 18 patients and confirmed the continued sup-
pression of parathyroid function for 12 weeks after PMIT
(serum iPTH, adjusted serum Ca and P levels before
and immediately, 4, and 12 weeks after PMIT, 992 
461, 348  246, 560  313, and 459  256 pg/mL, P 
0.01; 11.3  0.67, 11.7  1.15, 11.1  0.91, and 11.7 
Fig. 2. Time course changes in serum intact-PTH, adjusted serum cal-
cium (Ca), and phosphorus (P) levels (N  18). The decrease in serum
intact-PTH levels continued for 12 weeks after percutaneous maxacalci-
tol injection therapy (PMIT) without significant changes in both ad-
justed serum Ca and P levels. *P  0.01 vs. before PMIT.
Fig. 3. Changes in serum bone alkaline phosphatase (BAP) and intact
bone Gla-protein (iBGP) levels before and 12 weeks after percutaneous
maxacalcitol injection therapy (PMIT) (N  18). Serum iBGP levels
significantly decreased 12 weeks after PMIT. *P 0.05 vs. before PMIT.
0.98 mg/dL; and 6.73  1.54, 6.32  1.05, 6.48  1.48,
and 6.00  1.20 mg/dL, respectively) (Fig. 2). Moreover,
levels of bone markers tended to decrease after PMIT
and the subsequent intravenous OCT administrations.
In particular, serum iBGP levels significantly decreased
(serum BAP and iBGP levels before and 12 weeks after
PMIT, 227  150 vs. 177  120 IU/L, 284  191 vs.
212  156 ng/mL, P  0.05, respectively) (Fig. 3). Total
parathyroid gland volumes also significantly decreased
12 weeks after PMIT compared with those before PMIT
(1.98  1.28 vs. 1.26  0.79 cm3, P  0.01, respectively)
(Fig. 4A). Particularly for more severely swollen para-
thyroid glands before PMIT, the ratio of parathyroid
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Fig. 4. Changes in parathyroid gland volume before and 12 weeks after
percutaneous maxacalcitol injection therapy (PMIT) (N  18). (A )
Total parathyroid gland volume significantly decreased after PMIT and
the subsequent intravenous maxacalcitol (OCT) administrations. (B )
Changes in individual parathyroid gland volumes 12 weeks after PMIT
compared with before PMIT for each size are shown. For the larger
parathyroid glands before PMIT, the regressive ratios of parathyroid
gland volume were higher (PGv  /6  0.53, /6  0.53  PGv 
/6  1.03, /6  1.03  PGv  /6  1.53 and PGv  /6  1.53 cm3;
8, 40, 9 and 8 glands; 18 patients were examined, respectively). PGv is
parathyroid gland volume. *P  0.01 vs. before PMIT.
gland volume (PGv) after 12 weeks with respect to that
before PMIT was lower than that of mildly swollen para-
thyroid glands (PGv  /6  0.53, /6  0.53  PGv 
/6  1.03, /6  1.03  PGv  /6  1.53, PGv  /6 
1.53 cm3; 393  315, 96.1  94.6, 62.2  47.8, and 53.2 
22.1%, respectively) (Fig. 4B). Table 4 shows the individ-
ual laboratory data in all patients and those 24 weeks
after PMIT followed by intravenous OCT administra-
tions in 14 patients.
Morphologic changes after PMIT
Figure 5 a, b, e, f, i, j, m, and n show light microscopy
images of biopsied parathyroid gland specimens before
and after PMIT. In Figure 5 a, e, i, and m (before PMIT),
numerous parathyroid cells are observed, indicating hy-
perplasia. After PMIT, some partial defects of parathy-
roid cells were observed, and some of the parathyroid
cells were observed to have condensed and fragmented
nuclei, which are considered the expressions of cell apo-
ptosis (Fig. 5b). Moreover, Figure 5 f, j, and n show the
existence of many parathyroid cells and the abnormal
structure of parathyroid tissue. Most of the nuclei in
these parathyroid cells were condensed.
Analysis of apoptosis induced by PMIT
Analysis of parathyroid tissues by the TUNEL method
revealed distinct patterns of staining of TUNEL-positive
cells [brown spots; diaminobenzidine (DAB)] and
TUNEL-negative cells (green spots; methyl green). Fig-
ure 5 c, d, g, h, k, l, o, and p show apoptotic parathyroid
cells stained by the TUNEL method before and after
PMIT. In the specimens obtained before PMIT, few or
no apoptotic cells were observed (Fig. 5 c, g, k, and o), but
after PMIT, a number of apoptotic (TUNEL-positive)
parathyroid cells were noted (Fig. 5 d, h, l, and p). Some
of the apoptotic cells were scattered in the specimen, but
most of them were found in one segment. Furthermore,
boundaries between the segment of apoptotic cells and
that of non-apoptotic cells were clear. From these find-
ings, the TUNEL method revealed a significant increase
in the number of TUNEL-positive cells (expressed per
1000 cells) in parathyroid tissues obtained after PMIT
as compared with those before PMIT (rates of TUNEL-
positive cells before and after PMIT, 1.08 1.66 vs. 619
58.2/1000 cells; P  0.01, N  13, respectively) (Fig. 6).
By DNA electrophoresis of parathyroid tissues ob-
tained after PMIT, a ladder pattern indicating the pres-
ence of DNA fragmentation, a characteristic feature of
cell apoptosis [12], was observed; this feature was not
observed before PMIT (Fig. 7). This change was con-
firmed in all 7 patients in whom DNA for parathyroid
cells were extracted and examined.
Changes in PTH mRNA level determined
by RT-PCR
Figure 8A shows the representative changes in PTH
and GAPDH mRNA levels in parathyroid tissues before
and after PMIT. The PTH mRNA level after PMIT
clearly decreased in comparison with that before PMIT,
but the GAPDH mRNA level did not change. Figure 8B
shows the comparison of the average of PTH/GAPDH
mRNA ratio between before and after PMIT. After
PMIT, this ratio significantly decreased compared with
that before PMIT; an average of 0.452  0.98-fold de-
crease in the PTH mRNA level was observed (P  0.01,
N  8).
DISCUSSION
OCT is a vitamin D analog developed to strongly sup-
press parathyroid function with low calcemic and phos-
phatemic actions. Thus, OCT is now benefiting many
dialysis patients with SHPT in Japan. However, there are
some patients with SHPT resistant to OCT intravenously
administered because of its poor suppressive effects on
PTH and/or complications such as hypercalcemia. For
the treatment of these refractory SHPT, PMIT has been
developed.
Kitaoka et al [3] reported the efficacy and safety of
direct calcitriol injection into parathyroid glands 3 times
a week for 2 weeks and showed the necessity of following
it up with calcitriol pulse therapy. On the other hand,
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we utilized the same therapeutic method but injected
OCT consecutively 6 times a week, and found that PMIT
could markedly suppress parathyroid function and re-
duce the parathyroid gland volume without significantly
changing serum Ca and P levels. It has been considered
that the calcemic and phosphatemic actions of OCT and
the elevated serum concentration of OCT applied fol-
lowing PMIT contributed little to these effects because
serum Ca and P levels did not significantly change during
the period of PMIT, and we confirmed that the serum
OCT concentration following PMIT was not markedly
elevated, in spite of PMIT with a total OCT dose of 30
g/PMIT, and that serum OCT cleared off rapidly (data
not shown). Therefore, it has been considered that the
excessive elevation of intra-parathyroid gland OCT con-
centration by PMIT played the most important role in
the expression of these effects. Furthermore, PMIT did
not cause aggravated injury of surrounding tissues, which
was observed in PEIT, such as laryngeal palsy. PMIT
was performed on all detectably enlarged parathyroid
glands simultaneously, even if these enlarged parathy-
roid glands existed bilaterally. All the patients showed
tolerance to PMIT. Thus, PMIT was confirmed to clini-
cally improve and to be safe for refractory SHPT. More-
over, these effects were not temporary but continued for
at least 12 weeks. Thus, this continued suppression of
SHPT, as shown by the significant decrease in the serum
iBGP level, might contribute to improving the high
bone–turnover disease caused by SHPT. Table 5 shows
the clinical outcomes of PMIT. SHPT in 13 of 18 patients
could be controlled for more than 48 weeks by following
up PMIT with intravenous OCT administrations. One
patient (patient no. 9) required PMIT again 48 weeks
after the first series of PMIT because of the re-elevation
of the serum iPTH level (serum iPTH levels before, 24,
and 48 weeks after PMIT, 1500, 203, and 482 pg/mL,
respectively). Four patients required PEIT 12 weeks
after PMIT because of insufficient suppression of origi-
nally severe SHPT. The continuation of high serum Ca
level for more than 12 weeks indicates the necessity
of discontinuing OCT intravenously administered and
treatment by PEIT or PTx-AT instead. These 5 patients
had more severely swollen parathyroid glands before
PMIT and/or their serum Ca levels increased in the early
phase after PMIT. Therefore, it is suggested that PMIT
is indicated for patients without a parathyroid gland vol-
ume of more than 2 cm3 or severely high levels of P
and/or PTH (serum P and iPTH levels more than 9.0
mg/dL and/or 1500 pg/mL, respectively). Regarding the
parathyroid gland volume reduction by PMIT and subse-
quent OCT intravenous administrations, the parathyroid
gland volumes 12 weeks after PMIT were contrarily in-
creased in the smallest group with a parathyroid gland
volume of less than /6  0.53 cm3 (Fig. 4B). Therefore,
it is not necessary for parathyroid glands with a volume
of less than /6  0.53 cm3 to be treated by PMIT. How-
ever, the most important point is the possibility that all
glands can be treated by PMIT in the case without ec-
topic parathyroid glands. Therefore, it is necessary to
rule out the existence of ectopic parathyroid glands by
99mTc-MIBI or Tl-Tc; in fact, we excluded one patient
with ectopic parathyroid gland in the upper mediastinum
from this study.
Next, the mechanisms underlying the suppression of
parathyroid function by PMIT were studied. As one of
the mechanisms, OCT was shown to suppress the synthe-
sis and secretion of PTH, as proven by the reduction in
the PTH mRNA level [7, 8, 13]. The in vivo effect of
the suppression of PTH synthesis and secretion by PMIT
was observed in this study (Figs. 1 and 8). It is considered
the suppression of PTH gene transcription by OCT ad-
ministered at a high concentration that may mostly con-
tribute to the early-stage regression of SHPT by PMIT.
As an explanation for the continued improvement of
SHPT following PMIT and the subsequent intravenous
OCT administrations, the reduction in the parathyroid
gland volume was suggested to be one of the underlying
factors. Morphologic findings in parathyroid tissues ob-
tained after PMIT showed not only some partial defects
of parathyroid cells but also condensation and fragmen-
tation of nuclei in many of the extant parathyroid cells.
This finding suggests that the decrease in the number of
parathyroid cells is partially caused by the induction of
apoptosis by PMIT. First, we showed the marked increase
in the number of TUNEL-positive parathyroid cells after
PMIT (from 1.08  1.66 to 619  58.2/1000 cells) (Figs.
5 d, h, l, p, and 6). Biopsies of the biggest parathyroid
gland of each patient were performed (Table 2), and
Figure 4B shows the greater reduction in the parathyroid
gland volume in bigger parathyroid glands before PMIT.
Thus, it is considered that many cells in biopsied parathy-
roid glands underwent apoptosis induced by PMIT (the
mean ratio of parathyroid gland volume 12 weeks after,
with respect to that before PMIT in biopsied parathyroid
glands was lower than that in nonbiopsied parathyroid
glands without less than /6  0.53 cm3; 66.2 and 89.7%,
respectively). Parathyroid gland specimens were ob-
tained by needle biopsies from the center of each gland
for safety and accuracy. PMIT was performed in various
sites of each parathyroid gland, but most of the maxacal-
citol was injected into the center and extended to the
periphery. Thus, the parathyroid gland specimens were
obtained from parts most greatly influenced by PMIT
and it is considered these parts contained more TUNEL-
positive cells than any other part in each parathyroid
gland. Thus, it is considered that our result (i.e., the
marked increase in the ratio of TUNEL-positive cells
with respect to the total number of parathyroid cells)
was exaggerated by these factors. For the exclusion of
heterogeneous TUNEL-positive cells in the biopsied
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Fig. 5. Light microscopy and detection of DNA fragmentation by terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL)
method in serial sections. (a, e, i, m ) Representative light microscopy images of parathyroid tissue before and (b, f, j, n ) after percutaneous
maxacalcitol injection therapy (PMIT) are shown. Before PMIT, a number of hyperplastic parathyroid cells were observed (a, e, i, m), but (b)
after PMIT, few parathyroid cells with partial defects and those exhibiting condensation and fragmentation of nuclei, which are considered the
expressions of cell apoptosis, were observed. Many parathyroid cells were observed; however, most of their nuclei were condensed (f, j, n).
Representative findings of in situ detection of DNA fragmentation in parathyroid tissues by the TUNEL method (c, g, k, o) before and (d, h, l, p)
after PMIT are shown. (c, g, k, o) Before PMIT, no or few apoptotic (TUNEL-positive) cells were observed but (d, h, l, p) after PMIT, a number
of apoptotic parathyroid cells were noted. The magnification of all figures: 1, low magnification, 2, high magnification, respectively.
specimens, we performed the same TUNEL method on
more than 30 parathyroid glands obtained by surgical
excisions in patients administered with OCT intrave-
nously immediately before the operations, and con-
firmed the ratio of TUNEL-positive cell to be similar to
the specimens obtained before PMIT (data not shown)
or a previous report [14]. Second, it is well known that
nonspecific TUNEL-positive cells such as necrotic cells
are often observed, so we performed DNA electrophore-
sis on parathyroid gland specimens before and after
PMIT in 7 patients. A ladder pattern indicating the pres-
ence of DNA fragmentation, which is characteristic of
cell apoptosis [12], was observed only in specimens ob-
tained after PMIT, and this phenomenon was observed
in all 7 patients in whom DNA in parathyroid gland was
analyzed. Moreover, we investigated the induction of
apoptosis in parathyroid glands surgically opened and
directly injected with OCT or its vehicle in uremic rats.
The ratios of TUNEL-positive parathyroid cells in rats
injected with OCT were significantly higher than those
in rats injected with its vehicle, and the ladder pattern
was also observed on parathyroid glands injected with
OCT (data not shown). Therefore, the induction of apo-
ptosis following PMIT is caused neither by the effects
of the vehicle nor mechanical and pressure injury.
Previously, Fukagawa et al [10] reported a significant
decrease in the parathyroid gland volume following
calcitriol oral pulse therapy for 12 weeks and hypothe-
sized that the apoptosis of parathyroid cells is induced
by calcitriol at high concentrations. In contrast, Quarles
et al [15] failed to observe a decrease in parathyroid
gland volume in hemodialysis patients in response to
calcitriol pulse therapy for 36 weeks, as assessed by ultra-
sound and/or magnetic imaging. In animals, a very high
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Fig. 5. (Continued)
dose of calcitriol [equivalent to that for a 70 kg human
(145.6g)] intraperitoneally administered did not induce
apoptosis of parathyroid cells [16]. Moreover, an in vitro
study showed the inhibition of cell apoptosis by calcitriol
at high concentrations in hyperplastic parathyroid tissues
from patients with SHPT [17]. However, all of these
previous studies focused on the induction of apoptosis
by calcitriol only. A recent study indicated the possibility
that OCT differs from calcitriol in terms of its biologic
effect through the interactions of VDR with specific co-
activators [18]. Therefore, we presumed that the mecha-
nism underlying the induction of apoptosis by PMIT
might be the specific effect of OCT on the VDR signaling
pathway of parathyroid cells. Furthermore, reports sup-
porting our hypothesis that there is a relationship be-
tween vitamin D and cell apoptosis in various tissues
and cell lines have been published recently. In particular,
in Wilms’ tumor, gene product (WT1)-expressing renal
embryonic cells, Wagner et al [19] suggested that tran-
scriptional activation of VDR by WT1 mediates apopto-
sis of these cells. In myeloma [20], breast cancer [21],
colorectal carcinoma [22], and melanoma cells [23], an
obvious relationship between vitamin D and cell apopto-
sis was reported. In addition, Hewison et al [24] reported
that VDR antisense transfection inhibits the induction
of apoptosis in the monoblastoid cell line. Nakagawa et al
[25] reported that stimulation of VDR/RXR/vitamin D
response elements (VDRE) complex formation induces
apoptosis of promyelocytic leukemia cells. Guzey et al
[26] reported that vitamin D induces decreases in the
levels of antiapoptotic proteins such as Bcl-2 in associa-
tion with enhancement of apoptosis in prostate cancer.
Based on these previous reports and our data, we suggest
that one of the mechanisms for the regression of SHPT is
apoptosis via VDR in parathyroid cells. In our specimens
obtained after PMIT, parathyroid cells, which showed
immunohistochemical staining of VDR, tended to show
TUNEL-positive simultaneously. However, a more in-
depth study is necessary to elucidate the details of this
biologic reaction.
The biologic response to OCT that leads to the sup-
pression of PTH synthesis is considered to be due to the
control of the gene transcription mediated by a nuclear
receptor (VDR) in target cells. However, nodular hyper-
plasia shows a more marked decrease in the content of
VDR on parathyroid cells [27], thus advanced SHPT
shows resistance to vitamin D administration. In dialysis
patients, bolus oral or intravenous calcitriol administra-
tion not only reduced PTH levels, but also improved the
response to calcitriol by VDR up-regulation in parathy-
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Fig. 6. Change in ratios of terminal deoxynucleotidyl transferase-medi-
ated dUTP nick end-labeling (TUNEL)-positive parathyroid cells fol-
lowing percutaneous maxacalcitol injection therapy (PMIT). TUNEL-
positive parathyroid cell ratios significantly increased after PMIT (N 
13). *P  0.01 vs. before PMIT.
Fig. 7. DNA fragmentation observed by 2% agarose gel electrophore-
sis. The ladder pattern indicating the presence of DNA fragmentation,
which is a characteristic of cell apoptosis, was observed after percutane-
ous maxacalcitol injection therapy (PMIT). This feature was not ob-
served before PMIT. This change was observed in all 7 patients in
whom DNA for parathyroid cells were extracted and examined.
Fig. 8. Effect of percutaneous maxacalcitol injection therapy (PMIT)
on parathyroid hormone (PTH) mRNA levels. Representative changes
in PTH mRNA levels in parathyroid glands following PMIT determined
using reverse transcription-polymerase chain reaction (RT-PCR) are
shown. (A ) These levels decreased after PMIT without obvious changes
in GAPDH mRNA levels. (B ) After PMIT, PTH/GAPDH mRNA
ratios obtained by densitometric analysis significantly decreased com-
pared with that before PMIT (N  8). *P  0.01 vs. before PMIT.
Table 5. Clinical outcomes after PMIT
Clinical outcomes Number of patients (patient no.a)
Good control by i.v. OCTb 13
Re-PMITc 1 (patient no. 9)
PEITd 4 (patient no. 6, 11, 12, and 15)
Abbreviations are: OCT, maxacalcitol; Re-PMIT, re-percutaneous maxacalci-
tol injection therapy; PEIT, percutanous ethanol injection therapy.
a Patient no. is the same as that shown in Table 2
b These patients were controlled by the subsequent intravenous (i.v.) OCT
administrations for more than one year
c This patient was treated by the same series of PMIT again immediately one
year after the first series
d These patients were treated by PEIT due to the insufficient suppression of
parathyroid hormone levels and severely elevated serum Ca levels for 12 weeks
after PMIT
roid cells [13, 28–30]. Intraperitoneal administration of
OCT has also been reported to induce VDR up-regula-
tion in parathyroid cells of uremic rat [9]. In the present
study, the number of parathyroid cells immunohisto-
chemically stained by the monoclonal anti-VDR anti-
body tended to increase, thus it is presumed that VDR
up-regulation by PMIT is another factor that contributes
to amplifying the effects of PMIT followed by intrave-
nous OCT administrations and to the continued regres-
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sion of SHPT for a long period. For the up-regulation
of VDR in parathyroid cells following direct OCT injec-
tions, we have confirmed the time course of VDR con-
tents in rat parathyroid gland directly injected with OCT
by both RT-PCR and immunohistochemical study (data
not shown). However, it is considered that more precise
studies are required to elucidate the mechanisms under-
lying the effect of PMIT.
CONCLUSION
We have clarified that PMIT could reduce not only
serum iPTH levels but also the volume of parathyroid
glands without major complications. Our results suggest
that the suppression of PTH synthesis and secretion, and
the decreased number of parathyroid cells due to the
induction of apoptosis by OCT at a very high concentra-
tion in the parathyroid gland are contributing factors to
the regression of SHPT by PMIT.
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